HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy The ...
Mersana Therapeutics has reported encouraging preliminary data from the Phase 1 trial of its lead antibody-drug conjugate, emiltatug ledadotin (Emi-Le), which targets B7-H4 in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback